Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) believes that in the future, up to 80 percent of its total revenue could stem from licensing deals for its patented DehydraTECH™ delivery technology. An article discussing the company reads: “The company’s patented DehydraTECH™ is key to LXRP’s valuation. The technology is being tested in human clinical studies for the delivery of cannabinoids through ingestible means. Results thus far have shown increased absorption rates with reduced time to enter the bloodstream and reported improvements in the taste and smell of edible products. … Lab tests on mice have shown a 50 percent improvement in active ingredients, such as nicotine, being absorbed into the bloodstream. They demonstrated even higher percentage levels absorbed into the brain. Bunka said that these results could potentially have an important impact on future treatment of cancer and brain tumors.”
To view the full article, visit http://cnw.fm/7DcQI
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. develops and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the U.S. and Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
More from CannabisNewsBreaks
About HempWire
HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/
HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
Golden Triangle Ventures (OTC: GTVH) (“GTV”) has completed a major restructuring of its capital structure and…
InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with…
CannabisNewsWire (CNW), a trusted communications platform within the cannabis sector and a part of InvestorBrandNetwork…
Turning Point Brands (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, recently…
WEED Inc. (OTCQB: BUDZ), a global cannabis and hemp bioresearch company based in the U.S.,…
Flora (NASDAQ: FLGC) has closed a registered direct offering to institutional investors for the aggregate…